-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE…
The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health…
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment…
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a…
MELBOURNE, Australia and SAN FRANCISCO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the…
New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial…
In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the…
Azenosertib Fast Track Designation granted for Cyclin E1 positive patients by U.S. Food and Drug Administration (FDA) Manuscript focused on role…
Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered…
Sharing Insights at the 'Italy on the Move' Event and Engaging Investors at Biotech Showcase During JPM Healthcare Week in…